Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Maldox vs G-COSPE in Healthy Subjects
NCT04577469Phase 1Unknown
- Sponsor
- Emzor Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of sulfadoxine + pyrimethamine in malaria (2 arms), sponsored by Emzor Pharmaceuticals. Primary endpoints: Peak Plasma Concentration for Sulfadoxine and Pyrimethamine at 12 weeks and Area under the plasma concentration versus time curves at 12 weeks. Status: unknown.
02
Drugs
sulfadoxine + pyrimethamine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04577469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577469.